Price Chart

Profile

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
URL https://www.royaltypharma.com
Investor Relations URL https://www.royaltypharma.com/investors
HQ State/Province New York
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Value
Next Earnings Release May. 09, 2024 (est.)
Last Earnings Release Feb. 15, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Feb. 15, 2024

Profile

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
URL https://www.royaltypharma.com
Investor Relations URL https://www.royaltypharma.com/investors
HQ State/Province New York
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Value
Next Earnings Release May. 09, 2024 (est.)
Last Earnings Release Feb. 15, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Feb. 15, 2024